Xiwen Zhang

Xiwen Zhang

Auto-generated profile, based on publicly available information

Xiwen Zhang

Department of Dermatology West China Hospital, Sichuan University Chengdu China

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 January 2024 in The Journal of Dermatology
Verified
Journal Article
Closed access
XZXiwen Zhang
Xiwen Zhang
YXYue Xiao
Yue Xiao
XLXiaohong Li
Xiaohong Li
JWJinqiu Wang
Jinqiu Wang
XZXingli Zhou
Xingli Zhou
WLWei Li
Wei Li

25 March 2024 in Journal of Investigative Dermatology
Verified
Journal Article
Closed access
YWYiyi Wang
Yiyi Wang
SZShan Zhao
Shan Zhao
XZXiwen Zhang
Xiwen Zhang
DXDeng-mei Xia
Deng-mei Xia
YXYue Xiao
Yue Xiao
WLWei Li
Wei Li

5 May 2025 in The Journal of Dermatology
Verified
Journal Article
Closed access
MZMin Zou
Min Zou
KZKun Zhan
Kun Zhan
XFXun Feng
Xun Feng
JLJishu Li
Jishu Li
MWMintong Wei
Mintong Wei
WLWei Li
Wei Li

1 January 2023 in Dermatologic Therapy
Verified
Journal Article
Open access
PDF file
YXYue Xiao
Yue Xiao
XZXiwen Zhang
Xiwen Zhang
XFXun Feng
Xun Feng
JGJingya Gao
Jingya Gao
FLFurong Li
Furong Li
WLWei Li
Wei Li
Background. The global impact of coronavirus 2019 (COVID‐19) has raised concerns about the management of psoriasis patients, especially among those using biologics. Methods. We conducted a survey‐based research among Omicron‐infected (confirmed, probable, and suspected ones) psoriasis patients in the department of dermatology, West China Hospital, Sichuan University, from January 9th to January 22nd, 2023. We collected demographic and clinical information (psoriasis‐ and COVID‐19‐related) and conducted statistics analysis. Results. Of the 240 patients enrolled, they were classified by the psoriatic treatment, as biologics (n = 138), nonbiological systematic treatment (n = 52), and topical treatment or without pharmacological treatment (n = 50). This study showed the characteristics of Omicron‐related symptoms and cutaneous signs in patients. We observed that patients who received topical treatment or without pharmacological treatment had a lower risk of presenting with COVID‐19 symptoms in the fully adjusted logistic model (OR = 0.40, 95% CI: 0.18–0.90, and P = 0.025). Moreover, in the model for skin manifestations, nonbiological systematic treatment (OR = 2.15, 95% CI: 1.08–4.27, and P = 0.029) and high BMI (OR = 1.10, 95% CI: 1.00–1.20, and P = 0.042) were correlative factors. Conclusions. Our data suggested that differential psoriatic treatment might be a correlative factor in developing symptomatic or asymptomatic Omicron infection and presenting cutaneous signs.